You are here: Industry Insights > CSL

News List

Mustang Bio, CSL Behring Enter License Agreement for Stable Producer Cell Line contractpharma
August 28, 2019
Cytegrity™ is a stable producer cell line developed by St. Jude Children’s Research Hospital for the treatment of X-linked severe combined immunodeficiency.
Aslan Pharmaceuticals amends license agreement with CSL biospectrumasia
June 03, 2019
Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004
CSL marks a billion dollar in profits biospectrumasia
October 24, 2018
BioSpectrum Asia Top 20 Survey Rank 2 - CSL, Australia
CSL to purchase 80% stake in Chinese firm Ruide for $352m pharmaceutical-technology
June 15, 2017
Global biotechnology company CSL has agreed to buy 80% stake in Chinese plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products (Ruide) from Humanwell Healthcare Group for $352m.
CSL acquires major stake in Ruide China biospectrumasia
June 15, 2017
Within the Ruide joint venture, CSL will have an opportunity to contribute capabilities across the full range of plasma products currently produced by CSL in markets outside China.
CSL to Acquire Majority Stake in Chinese Plasma Fractionator Wuhan Zhong Yuan Rui De Biologicals Pro americanpharmaceuticalreview
June 14, 2017
CSL Limited has agreed to acquire 80 per cent equity of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.

Previous page 1 2 Next page